Differential antiseizure medication sensitivity of the Affective Reactivity Index: A randomized controlled trial in new-onset pediatric focal epilepsy

David W. Loring, Kimford J. Meador, Shlomo Shinnar, William Davis Gaillard, James W. Wheless, Sudha K. Kessler, Joan A. Conry, Madison M. Berl, Thomas G. Burns, Tracy A. Glauser, Becky Kinkead, Avital Cnaan

Research output: Contribution to journalArticle

Abstract

Background: Irritability is a adverse effect of many antiseizure medications (ASMs), but there are no validated measures currently available to characterize this behavioral risk. We examined both child and parent/guardian versions of the Affective Reactivity Index (ARI), a validated measure developed for application in adolescent psychiatry, to determine its sensitivity to ASM-related irritability. We hypothesized irritability increases associated with levetiracetam (LEV) but not lamotrigine (LTG) or oxcarbazepine (OXC). Method: The ARI was administered to 71 child and parent/guardian pairs randomized to one of three common ASMs (LEV, LTG, OXC) used to treat new-onset focal (localization-related) epilepsy. Subjects were recruited as part of a prospective multicenter, randomized, open-label, parallel group design. The ARI was administered at baseline prior to treatment initiation and again at 3 months after ASM initiation. Results: There was a significant increase in ARI ratings for both child and parent/guardian ratings for LEV but not LTG or OXC when assessed 3 months after treatment initiation. When examined on the individual subject level using a criterion of at least a 3-point ARI increase, there was an increase associated with LEV for child ratings but not parent/guardian scores. Conclusion: Both child and parent/guardian versions of the ARI appear sensitive to medication-induced irritability associated with LEV on both the group and individual levels. The findings extend the applicability of ARI from characterizing the presence of clinical irritability as a psychiatric diagnostic feature to a more modifiable aspect of behavior change related to medication management and support its use in clinical trial applications.

Original languageEnglish (US)
Article number106687
JournalEpilepsy and Behavior
Volume102
DOIs
StatePublished - Jan 2020

Keywords

  • Affective Reactivity Index
  • Antiseizure medications
  • Irritability

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Behavioral Neuroscience

Fingerprint Dive into the research topics of 'Differential antiseizure medication sensitivity of the Affective Reactivity Index: A randomized controlled trial in new-onset pediatric focal epilepsy'. Together they form a unique fingerprint.

  • Cite this

    Loring, D. W., Meador, K. J., Shinnar, S., Gaillard, W. D., Wheless, J. W., Kessler, S. K., Conry, J. A., Berl, M. M., Burns, T. G., Glauser, T. A., Kinkead, B., & Cnaan, A. (2020). Differential antiseizure medication sensitivity of the Affective Reactivity Index: A randomized controlled trial in new-onset pediatric focal epilepsy. Epilepsy and Behavior, 102, [106687]. https://doi.org/10.1016/j.yebeh.2019.106687